Kwantitatief immuno-oncologische test OncoTect iO gepubliceerd in nieuw onderzoek
MENLO PARK, Calif.–(BUSINESS WIRE)– IncellDx, Inc., een medisch bedrijf dat geneeskunde op celniveau bedrijft, heeft vandaag aangekondigd dat het internationale, peer-reviewed tijdschrift Cancer Immunology, Immunotherapy het manuscript heeft gepubliceerd met de titel: “Quantification of PD-L1 and PD-1 expression on tumor and immune cells in non-small cell lung cancer (NSCLC) using non-enzymatic tissue dissociation and flow cytometry.” Dr. Bruce Patterson, oprichter en ceo, legt hierin uit dat het een nieuwe, op één cel gerichte aanpak is bij de kwantificering van de expressie van PD-L1 en PD-1 op tumoren en immuuncellen bij niet-kleincellige longkanker. De methodologie is bewezen bij fijnnaaldbiopsie en tumorbiopsie. De monsters zijn niet-enzymatisch gehomogeniseerd in ééncellige suspensies met behulp van de kit IncellPREP™ van IncellDx voor het afnemen van een ééncellig monster, voordat een FFPE-blok wordt gemaakt.
IncellDx’s Quantitative Immuno-Oncology Assay OncoTect iO Published in New Study
MENLO PARK, Calif.–(BUSINESS WIRE)– IncellDx, Inc., a single cell, precision medicine company, today announced that the international peer-reviewed medical journal Cancer Immunology, Immunotherapy has published a manuscript entitled: “Quantification of PD-L1 and PD-1 expression on tumor and immune cells in non-small cell lung cancer (NSCLC) using non-enzymatic tissue dissociation and flow cytometry.” Dr. Bruce Patterson, MD, Founder and CEO explained that this is a novel, single cell approach to quantifying the expression of PD-L1 and PD-1 expression on tumor and immune cells in non-small cell lung cancer (NSCLC) tumor samples. The methodology has been validated on both fine needle aspiration (FNA) and tumor biopsies. The samples are non-enzymatically homogenized into single cell suspensions using IncellDx’s IncellPREP™ kit yielding a single-cell sample before a formalin-fixed paraffin embedded (FFPE) block is made.
As Dr. Patterson explained, “We believe this objective quantitation of PD-L1 expression in tumor and immune cells in NSCLC will allow for better prediction of patient response to the new PD-1 immunotherapies within a work flow that is suited well for primary indications where the initial diagnosis may be made using several approaches to sampling the tumor. Further, the assay and sample preparation are automated allowing for same day turn around.”
The PD-L1 and PD-1 assay is the first release of IncellDx, Inc.’s newest family of single cell, multi-parametric molecular products called OncoTect® iO for immuno-oncology in a multitude of tissue types. The paper is now available online athttp://link.springer.com/article/10.1007/s00262-016-1889-3.
About IncellDx Inc.
IncellDx, Inc. is a single cell diagnostics company committed to advancing Precision Medicine by offering transformative diagnostic and prognostic clinical patient information based on an innovative technology platform that enables simultaneous cell classification and single cell analysis of proteomic and genomic biomarkers. The Company develops products designed to address pressing unmet clinical needs in the advancement of cancer care in addition to its virology products.
For more information, please visit www.incelldx.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20161004005461/en/
Contacts
IncellDx, Inc.
Chris Meda, +1-650-777-7630